D. Gonzalez-de-castro, P. Clarke, B. Lazikani, and P. Workman, Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance, Clinical Pharmacology & Therapeutics, vol.93, issue.3, pp.252-259, 2013.
DOI : 10.1016/j.cell.2012.02.009

D. Slamon, L. , B. Shak, S. Fuchs, H. Paton et al., Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001.
DOI : 10.1056/NEJM200103153441101

M. Peeters, T. Price, A. Cervantes, A. Sobrero, M. Ducreux et al., Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.28, issue.31
DOI : 10.1200/JCO.2009.27.6055

C. Soc, E. Van-cutsem, C. Köhne, I. Láng, G. Folprecht et al., Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update, 2011?2019. 5. Wells SA Jr, 2010.

S. Jasim, A. Ying, S. Waguespack, T. Rich, E. Grubbs et al., M918T Mutation, Thyroid, vol.21, issue.2, pp.189-192, 2011.
DOI : 10.1089/thy.2010.0328

V. Rohmer, G. Vidal-trecan, A. Bourdelot, P. Niccoli, A. Murat et al., Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline utatio: a ulticeeter study of the Groupe Fraacais

N. Agrawal, Y. Jiao, M. Sausen, R. Leary, C. Bettegowda et al., Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas, E2031?2035. 10. Moura MM, pp.863-868, 2011.

R. Elisei, B. Cosci, C. Romei, V. Bottici, G. Renzini et al., Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study Multikinase inhibitors: a new option for the treatment of thyroid cancer Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial al. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy, 682?687. 12617?624. 14. Wells SA, pp.134-141, 1990.

G. Hajje, I. Borget, S. Leboulleux, C. Chougnet, A. Ghuzlan et al., Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy, European Journal of Endocrinology, vol.168, issue.2
DOI : 10.1530/EJE-12-0771

H. Choi, C. Charnsangavej, S. Faria, H. Macapinlac, M. Burgess et al., Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria Molecular genetics and diagnosis of thyroid cancer, 1753?1759. 18. Nikiforov YE, Nikiforova MN, pp.569-580, 2007.

C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl et al., Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.8, pp.2892-2899, 2006.
DOI : 10.1210/jc.2005-2838
URL : https://hal.archives-ouvertes.fr/hal-00176664

S. Sherman, Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma, Clinical Oncology, vol.22, issue.6
DOI : 10.1016/j.clon.2010.03.014

. J. Eur, . Cancer-oxf, R. Tufano, G. Teixeira, J. Bishop et al., BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore). sept 2012 Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer, 274?286. 23. Xing M, 1990.

. Assoc, 10 avr 2013, pp.1493-1501

G. Riesco-eizaguirre, I. Rodríguez, D. Vieja, A. Costamagna, E. Carrasco et al., The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer Improved survival with vemurafenib in melanoma with BRAF V600E mutation, 8317?8325. 25. Chapman PB, pp.2507-2516, 2009.

K. Kim, M. Cabanillas, A. Lazar, M. Williams, D. Sanders et al., Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring V600EBRAF Mutation 14 mars 2013 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation, Thyroid Off. J. Am. Thyroid Assoc Cancer Discov. mai J. Clin. Invest. déc, vol.273121, issue.512, pp.4700-4711, 2011.

A. Ho, R. Grewal, R. Leboeuf, E. Sherman, D. Pfister et al., Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer, New England Journal of Medicine, vol.368, issue.7, pp.623-632, 2013.
DOI : 10.1056/NEJMoa1209288

R. Jensen, M. Berna, D. Bingham, and J. Norton, Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies, Cancer, vol.9, issue.5B, pp.1807-1843, 2008.
DOI : 10.1002/cncr.23648

Y. Jiao, C. Shi, B. Edil, R. De-wilde, D. Klimstra et al., DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors, Science, vol.331, issue.6021, pp.1199-1203, 2011.
DOI : 10.1126/science.1200609

E. Missiaglia, I. Dalai, S. Barbi, S. Beghelli, M. Falconi et al., Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway, Journal of Clinical Oncology, vol.28, issue.2, pp.245-255, 2010.
DOI : 10.1200/JCO.2008.21.5988

W. Hu, Z. Feng, I. Modica, D. Klimstra, L. Song et al., Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway, Genes & Cancer, vol.1, issue.4, pp.360-368, 2010.
DOI : 10.1177/1947601910371979

G. Rindi, G. Klöppel, H. Alhman, M. Caplin, A. Couvelard et al., TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system, Virchows Archiv, vol.80, issue.Suppl 4, pp.395-401, 2006.
DOI : 10.1007/s00428-006-0250-1

G. Rindi, M. Falconi, C. Klersy, L. Albarello, L. Boninsegna et al., TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study 16 mai 2012 Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB. 8 mars 2013 A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms, J. Natl. Cancer Inst Br. J. Cancer, vol.104108, issue.149, pp.1838-1845, 2013.

C. Durante, H. Boukheris, C. Dromain, P. Duvillard, S. Leboulleux et al., Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma Circulating tumor cells as prognostic markers in neuroendocrine tumors, Endocr. Relat. Cancer. juin J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 20 janv, vol.1631, issue.23, pp.585-597, 2009.

J. Zhang, Z. Jia, Q. Li, L. Wang, A. Rashid et al., Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors, Cancer, vol.23, issue.8, pp.1478-1486, 2007.
DOI : 10.1002/cncr.22554

J. Yao, M. Shah, T. Ito, C. Bohas, E. Wolin et al., Everolimus for advanced pancreatic neuroendocrine tumors Sunitinib malate for the treatment of pancreatic neuroendocrine tumors, N. Engl. J. Med. 10 févr N. Engl. J. Med. 10 févr, vol.364364, issue.66, pp.514-523, 2011.

M. Jafri, E. Maher, A. Gimenez-roqueplo, P. Dahia, M. Robledo et al., An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma Somatic HIF2A gain-offunction mutations in paraganglioma with polycythemia Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma, a novel therapy for anthracycline-and cisplatin-refractory malignant pheochromocytoma, ):328?333. 45. Burnichon N, pp.3974-3985, 2009.

C. Jimenez, M. Cabanillas, L. Santarpia, E. Jonasch, K. Kyle et al., Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.2, pp.386-391, 2009.
DOI : 10.1210/jc.2008-1972

M. Ayala-ramirez, C. Chougnet, M. Habra, J. Palmer, S. Leboulleux et al., Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas MGMT gene silencing and benefit from temozolomide in glioblastoma IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma, 4040?4050. 51. Hegi ME):997?1003. 52. SongTao Q, pp.269-273, 2005.

J. Bertherat, X. Bertagna, E. Baudin, H. Gelderblom, H. Haak et al., Adrenocortical Carcinoma Is a Lynch Syndrome-Associated Cancer Pathogenesis of adrenocortical cancer Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 261?271. 56. Berruti A, 2009.

M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak et al., Combination chemotherapy in advanced adrenocortical carcinoma Plasma coceetratios of o,p'DDD, o,p'DDA, aad o,p'DDE as predictors of tuor respose to itotaae i adrenocortical carcinoma: results of a retrospective ENS@T multicenter study, 2189?2197. 58. Hermsen IG,):1844?1851. 59. Terzolo M, pp.293-300, 2011.

G. Poli, D. Guasti, E. Rapizzi, R. Fucci, L. Canu et al., Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells Mitotaae therapy in adrenocortical cancer induces CYP3A4 and inhibits 5?-reductase, explaining the need for personalized glucocorticoid and androgen replacement Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial type I insulin-like growth factor receptor in adrenocortical carcinoma, 371?381. 63. Chortis V):297?305. 65. Kroiss M,):3495?3503. 66. Van Erp NP Mitotane has a strong and a durable inducing effect on CYP3A4 activity, pp.621-626, 2009.